Loading news...
NEWTON, Mass., Feb. 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,799 restricted stock units (RSUs) to four newly-hired employees.
Karyopharm Therapeutics Inc. (NASDAQ: KPTI - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $6.65 and traded as low as $6.36. Karyopharm Therapeutics shares last traded at $6.65, with a volume of 318,465 shares trading hands. Wall Street
Shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year
– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 – – Preliminary Unaudited Full Year 2025 Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue Expected to be Approximately $145 Million and $115 Million, Respectively – NEWTON, Mass., Jan. 12, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2025 total revenue and U.S. XPOVIO net product revenue estimates and outlined its 2025 achievements and 2026 objectives.
NEWTON, Mass., Jan. 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,533 restricted stock units (RSUs) to two newly-hired employees.
NEWTON, Mass. , Dec. 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on Wednesday, December 10, 2025 at 12:00 p.m.
NEWTON, Mass. , Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted a stock option to purchase an aggregate of 2,800 shares of Karyopharm's common stock and an aggregate of 15,791 restricted stock units (RSUs) to seven newly-hired employees.
NEWTON, Mass. , Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper Sandler 37th Annual Healthcare Conference in a fireside chat on Thursday, December 4, 2025 at 10:30 a.m.
NEWTON, Mass. , Nov. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 800 restricted stock units (RSUs) to one newly-hired employee.
Karyopharm Therapeutics Inc. ( KPTI ) Q3 2025 Earnings Call November 3, 2025 8:00 AM EST Company Participants Brendan Strong - SVP of Investor Relations & Corporate Communications Richard Paulson - President, CEO & Director Reshma Rangwala - Executive VP, Chief Medical Officer & Head of Research Sohanya Cheng - Executive VP, Chief Commercial Officer & Head of Business Development Lori Macomber - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Bank PLC, Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Colleen Hanley - Robert W. Baird & Co. Incorporated, Research Division Maurice Raycroft - Jefferies LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Jonathan Chang - Leerink Partners LLC, Research Division Presentation Operator Good morning.
– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Total Revenue was $44.0 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $32.0 Million, an increase of 8.5% compared to Third Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million and U.S. XPOVIO Net Product Revenue Guidance of $110 Million to $120 Million – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass.
-- Conference Call Scheduled for Monday, November 3, 2025, at 8:00 a.m. ET -- NEWTON, Mass.
Karyopharm Therapeutics Inc. (KPTI) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, KPTI's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Wednesday announced comprehensive financing and capital structure transactions expected to provide the company with $100 million of financial flexibility and additional capital, extending the cash runway into the second quarter of 2026.
– Transactions Provide Karyopharm with $100 Million of Financial Flexibility and Additional Capital – – Preliminary Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue for the Third Quarter of 2025 Expected to be in the Range of $42 to $44 Million and Approximately $32 Million, Respectively – – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – NEWTON, Mass. , Oct. 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into comprehensive financing and capital structure transactions expected to provide the Company with $100 million of financial flexibility and additional capital, extending the Company's cash runway into the second quarter of 2026 based on the Company's current operating plans.
NEWTON, Mass. , Oct. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 333 restricted stock units (RSUs) to one newly-hired employee.
Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
– Top-Line Results Anticipated in March 2026 – NEWTON, Mass. , Sept. 10, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has completed enrollment in the Phase 3 SENTRY trial, which is evaluating selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis patients.
NEWTON, Mass. , Sept. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 466 restricted stock units (RSUs) to two newly-hired employees.